News Lilly takes POINT in radiopharma push Eli Lilly has made a foray into the radiopharmaceuticals category with an agreement to buy POINT Biopharma for around $1.4 billion.
News Lantheus on POINT in radio-oncology with $2bn licensing deal Lantheus' pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma.
News GSK plans $800m US manufacturing investment GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US.
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.